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Objectives: This review summarizes recent developments in platelet biology relevant to neuroinflammatory
disorders. Multiple sclerosis (MS) is taken as the “Poster Child” of these disorders but the implications are wide. The
role of platelets in inflammation is well appreciated in the cardiovascular and cancer research communities but
appears to be relatively neglected in neurological research.
Organization: After a brief introduction to platelets, topics covered include the matrix metalloproteinases, platelet
chemokines, cytokines and growth factors, the recent finding of platelet PPAR receptors and Toll-like receptors,
complement, bioactive lipids, and other agents/functions likely to be relevant in neuroinflammatory diseases. Each
section cites literature linking the topic to areas of active research in MS or other disorders, including especially
Alzheimer’s disease.
Conclusion: The final section summarizes evidence of platelet involvement in MS. The general conclusion is that
platelets may be key players in MS and related disorders, and warrant more attention in neurological research.
Introduction
Platelets have long been implicated, or at least been sus-
pected, in the etiology of a variety of neuropathologies,
most obviously including ischemic stroke but also others
such as multiple sclerosis (MS). In recent decades, a ser-
ies of discoveries have been made which place those
conjectures on a sound rational footing. Broadly speak-
ing, the essence of these findings is that platelets possess
an unexpectedly large variety of receptors and secretory
products, additional to those serving their classical role
in hemostasis and thrombosis, which are active in
inflammation, immunity, and tissue repair. This versati-
lity is remarkable in view of their very small size and
lack of cell nuclei. Indeed, in the early days they were
regarded as nothing more than cellular debris. These
recent advances, together with the fact that platelets are
often the first cells to arrive at sites of vascular injury,
suggest the hypothesis that they may be central players
in neurodegenerative diseases.
As the title states, this review provides a wide-angle
perspective on platelets as mediators of inflammation
and immunity, with emphasis on neurological implica-
tions. Therefore, it is not possible to treat each topic in
the depth it deserves. Most of the topics are large and
specialized fields in themselves with their own wealth of
literature. However, the references supplied will lead the
interested reader to more comprehensive accounts.
Some good reviews of platelets in inflammation are
available [1] but the present review is more wide-ran-
ging and exhibits the relevance to neurology specifically
at every opportunity.
Platelet basics
Platelets, properly termed thrombocytes, were tradition-
ally considered to function exclusively in hemostasis and
thrombosis, a role for which they are superbly adapted.
Platelets are produced as fragments of megakaryocytes
and, according to the convincing arguments of Martin
[2], this fragmentation occurs during passage through
the lungs. Like erythrocytes, they lack nuclei but unlike
erythrocytes they do possess mitochondria. They are
about 1/4 the diameter of erythrocytes and about 1/24
as numerous, but they preferentially circulate along the
vessel wall [3], positioning them to respond immediately
to vascular injury.
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in intracellular calcium but platelets are most spectacu-
lar in this response, transforming irreversibly within sec-
onds from the resting discoid shape to extend numerous
pseudopodia, and becoming highly adhesive to each
other (aggregation), to other cells, and to almost any
surface, notably on collagen exposed in the sub-
endothelium, to form a platelet plug (white clot) [4].
However, weak agonists can induce partial and reversi-
ble activation ("priming”), which can be augmented
synergistically by other agents via multiple pathways,
and this primed state has been considered a target for
drug intervention [5]. Platelet activation is also accom-
panied by secretion, i.e. the release of numerous sub-
stances from specialized granules, as listed in Table 1
and a list of acronyms and alternative names of various
substances related to platelets is presented in Table 2. A
list of major platelet glycoproteins is given in Table 3
and Table 4 lists the principal natural agonists of plate-
lets and the receptors on which they act.
Equally important is the ability of activated platelets,
and microparticles from them which are released conco-
mitantly, to catalyze the coagulation cascade. This is
accomplished by an activation-dependent membrane
inversion or “flip-flop” by which normally in-facing
phospholipids (PL) become exposed to plasma [6].
These PLs are mainly anionic, such as phosphatidylser-
ine (PS), and render the membrane procoagulant by
promoting assembly of the vitamin K-dependent coagu-
lation factors into their active complexes (prothrombi-
nase and factor X-ase), to generate the thrombin that
converts fibrinogen to the fibrin plug. The role of
vitamin K in this process is to serve as a cofactor for
the post-translational addition of an extra carboxy group
to glutamic acid residues (Gla domains), enabling them
to bind calcium, much as citrate does, thereby anchor-
ing the coagulation factors to suitable PL membrane
surfaces (such as PS) via calcium bridging.
Since hemostasis and thrombosis is not the focus of
this article, readers wishing more depth are referred to
standard textbooks of hematology [7-10] or more spe-
cialized books [11].
Introduction to platelets as inflammatory
mediators
It had become clear by 1995 that platelets also play
major roles in inflammation and immunity [12-15]. This
concept was amply confirmed and extended by subse-
quent findings [16], beginning with the discovery around
the same time of the first chemokine receptor on plate-
lets (referenced below). The following paragraphs briefly
review the major classes of platelet-derived factors
which are active in inflammatory states, with emphasis
on implications for neurological disorders.
Matrix metalloproteinases in platelets
The matrix metalloproteinases (MMPs) are a group of
about 40 homologous proteases which are secreted to
the extra-cellular matrix (ECM) in an inactive form. As
a group these enzymes depend on a metal ion for activ-
ity, generally zinc. A subgroup of these enzymes, the
membrane-type (MT-MMP), remains at the plasma
membrane and can activate the secreted forms of the
enzyme. Other closely related enzymes are those of the
Table 1 Main Constituents of Platelet Secretory Granules
Dense Granules
Solutes 5HT, ADP, ATP, GDP, GTP, Ca, Mg, PyroPi, histamine
Membrane CD62P, CD63, GP’s Ib & IIb/IIIa, LAMP2, Src, Ral-1
Alpha Granules
Adhesive glycoproteins fibronectin, vitronectin, vWF, TSP
Proteoglycans PF4, ßTG, serglycin, HRGP & ßTG Ag’s: PBT, CTAP-III, NAP-2
Mitogens: PDGF, TGFß, ECGF, EGF, VEGF, VPE, IGF, IL-ß
Protease inhib’s TFPI, PAI-1, PDCI, a2-antiplasmin, C1 inhibitor, a2-antitrypsin, a2-macroglobulin
Coagulation: Factors V, XI, XIII, HMWK, fibrinogen, PAI-1, protein C, protein S, protein C inhibitor, TSP-1, TSP-2
Membrane* CD9, CD31, CD36, CD62P, CD144, GLUT-3,
* Not including several GP’s found also on plasma membrane
IgG, IgM, IgA, albumin, GP Ia/multimerin, osteonectin, clusterin, angiostatin, endostatin, plasminogen
Lysosomal Granules
(Lysosomes)
Acid proteases cathepsins D & E, carboxypeptidases A & B, collagenase, acid phosphatase, aryl sulfatase
Glycohydrolases heparinase, b-galactosidase, b-glucuronidase, b-N-acetyl-glucosaminodase, b-glycerophosphatse, b-D-glucosidase, a-
D-glucosidase, a-L-fucosidase, b-D-fucosidase, a-L-arabinosidase, a-D-mannosidase
Membrane LIMP-1, LAMP-1, -2
Dense Tubules Principal Ca store for internal secretion
Contents of the three main granules (dense, alpha, lysosomal) and the “dense tubules” are listed in Table 1.
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ADAMTS’s (ADAM with ThromboSpondin domain)
[17,18]. Many are also known by their earlier common
names. They have varying degrees of substrate specificity
towards many proteins in the vicinity of the ECM
including collagen, fibronectin, gelatin, laminin and
other stromal components ("stromelysins”). Accordingly,
their activities must be finely controlled and regulated
by the aforementioned activators, specific inhibitors
known as TIMP’s (Tissue Inhibitor of MMP), and by
the circulating plasma protein, alpha-2-macroglobulin.
MMPs are important in many aspects of human devel-
opment and tissue remodeling, and play significant roles
in pathogenesis of neuroinflammatory disorders.
MMPs have been generally recognized as major parti-
cipants in disruption of the blood-brain barrier (BBB) in
MS [19] and there is persuasive evidence that they play
a direct causal role [20]. This evidence consists of close
association of rising levels, particularly of MMP-9, prior
to onset of exacerbations in humans and in the animal
model of MS known as experimental autoimmune ence-
phalomyelitis (EAE) [21-23]. Relative reduction of
TIMP’s was also seen. In EAE model, disease severity is
sharply attenuated by inhibition of MMP or by gene
knockout. Similar results were observed with an alterna-
tive model of MS, demyelinating canine distemper virus
infection [24]. In human immunodeficiency virus (HIV)
infection, MMP-9 in particular was implicated in disrup-
tion of the BBB [25]. MMPs have also been implicated
in post-ischemic brain injury [26]. MMP-9 may be parti-
cularly noxious [27] but MMP-2 is also discussed as a
biomarker [28], as are others for the case of MS [20].
The mechanism usually proposed is that infiltrating leu-
kocytes employ MMPs to disintegrate the basement
membranes of cerebral endothelial cells to enter the
CNS.
Accordingly, inhibitors of MMPs are under active
investigation for treatmento fM Sa n ds o m eo t h e rn e u -
ropathologies [29]. At least one action of tetracycline
derivatives such as minocycline and doxycycline is inhi-
bition of MMPs [30-32]. Indeed, interferon-beta1a (IFN-
beta) is reported to have such action [33,34]. On the
other hand, several groups caution against prolonged
and non-specific inhibition of MMPs for therapy
because of their equally prominent role in repair, recov-
ery and normal CNS health [35-37].
How might platelets be placed in these events? First,
platelets have been shown to express MMPs -1, -2, -3,
- 9 ;A D A M - 1 0 ,- 1 7 ;a l lf o u rT I M P ’se x c e p tT I M P - 3 ;
MT1-MMP (also known as MMP-14); and ADAMTS-13
[38,39]. The cited review [38] is up-to-date but limits
discussion to the role of MMPs in platelet function and
does not explore the likely effects of MMPs secreted
during platelet activation on bystander cells, analogous
to the manner in which neutrophils or glial cells can
injure neurons in the vicinity [40]. Second, platelets are
often the first responders to sites of injury or inflamma-
tion. Third, it is known that platelets can interact with
Table 2 Main Constituents of Platelet Secretory Granules
Acronyms
5HT serotonin; 5-hydroxytryptamine NAP-2 neutrophil activating peptide-2
ADP, ATP adenosine diphosphate, -triphosphate PADGEM GMP-140. Former names for CD62P
CD144 Glut 3 PAI-1 plasminogen activator inhibitor 1
CD36 GP IV PBP platelet basic protein
CD62P P-selectin; see also PADGEM PDCI platelet-derived collegenase inhibitor
CTAP-III connective tissue activating protein III PDGF platelet-derived growth factor
EC endothelial cell PDGF platelet-derived growth factor
ECGF endothelial cell growth factor PECAM CD31; platelet-EC adhesion molecule
EGF epidermic growth factor PF4 platelet factor 4
Gbp guanine binding protein ßTG beta thromboglobulin
GDP, GTP guanine diphosphate, -triphosphate TFPI tissue factor pathway inhibitor
HMWK high molecular weight kininogen TGFß transforming growth factor ß
HRGP histidine-rich glycoprotein TSP thrombospondin
IGF insulin-like growth factor VEGF vascular endothelial growth factor
LAMP1, 2 lysosomal associated membrane prot VPF vascular permeability factor
LIMP, CD63 lysosomal integral membrane protein vWF von Willebrand factor
NAP-2 neutrophil activating peptide-2
The standard abbreviations used are spelled out in Table 2. The contents of each are classified in accordance with most of the sources. The main source was Ch.
7 of Gresele et al [11], with some updates from other sources such as [1]. Similar tables appear are found in textbooks of hematology but details may differ. For
example, Table twenty four to three of Colman et al [10] lists about twice as many acid hyrdrolases of the lysosomes. No attempt was made to give a complete
listing, i.e. many agents cited in text are not listed here. More details can be found in more recent or specialized sources such as [318]. The subcellular
localization of some recently identified secreted substances may not yet be known. Many proteins of the platelet plasma membrane are also found on the
membranes of granules and in the invaginations of the membrane known as the open canalicular system (OCS).
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strated by Rinder et al [41,42], extended by our labora-
tory to platelet microparticles (PMP) [43], and now
widely employed as an assay of activated or inflamma-
tory states, e.g. [44-47]. It has been shown that forma-
tion of platelet-leukocyte complexes is associated with
the expression and activation of MMPs -1, -2, -3 and -9
[48]. It is not clear in that paper if the source of MMP
is platelets or leukocytes (it is likely both) but inhibitors
of MMP in the media reduced formation of the com-
plexes while active MMP promoted them.
Fourth, is the effect of platelet-derived microparticles
(PMP). Although little work of a specifically neurological
nature has been done in this area, cancer researchers
have demonstrated that PMP strongly promote the inva-
sive potential of prostate and breast cancer cells in a
manner dependent on MMP expression [49-51], a pro-
cess resembling leukocyte infiltration to the CNS. PMP
express most of the platelet membrane proteins, there-
fore likely including MT-1 MMP, which was notable in
the study [51]. The work by Jy et al of our laboratory
demonstrated that PMP can directly activate and bind
to neutrophils [43]; however, MMP activities were not
measured. We have recently presented evidence that
cell-derived microparticles, especially PMP, may play an
important role in neurodegenerative diseases [52,53].
Although studies of platelet activation in MS are rare in
the recent literature, the data of Cananzi et al from
patients in remission clearly demonstrate chronic plate-
let activation in MS [54] (their figure two), confirming
earlier reports, which they cite, and which we discuss in
the closing section of this paper.
Platelet chemokines
Chemokines are central to inflammation chiefly by sig-
naling leukocyte migration/infiltration and differentia-
tion, but also by other actions [55]. About 50 are known
and half as many receptors. They are low molecular
weight proteins (7-12 kDa) and are known both by acro-
nyms for their common names and by systematic
nomenclature, the latter consisting of two main groups,
CC and CXC, and a few exceptions. These symbols
refer to the amino acids (aa), Cys-Cys or Cys-X-Cys
where X is any other aa. Suffix L for “ligand” or R for
“receptor” is applied. The alpha chemokines are the
CXCL’s and beta chemokines are the CCL’s. In general,
the CCL’sb i n do n l yt oC C R ’s, while CXCL’sb i n do n l y
to CXCR’s. Beyond that, the receptors are promiscuous
to varying degrees, suggesting complex and subtle sig-
naling depending on relative concentrations and affi-
nities of the ligands present.
T h ed i s c o v e r yo ft h ef i r s tc h e m o k i n er e c e p t o r so np l a -
telets around 1995 by Power et al [56-58] was a
watershed in platelet biology. This was followed by a suc-
cession of advances (e.g. [59-61]), leading to the present
knowledge of platelet chemokines, reviewed in 2003 [62],
2007 [63] and 2008 [64]. The 2007 review is particularly
clear but each brings out novel points. Platelet factor 4
(PF4), now called CXCL4, was the first known chemokine
(though not originally so named) and is secreted in abun-
dance from the alpha granules, along with about 10 other
platelet chemokines. In Table 5 a list of platelet chemo-
k i n e sa n dr e s p o n s e st ot h e mi sp r e s e n t e d .M o s to ft h e
work on platelet chemokines has been orientated to car-
diovascular disease. Useful insights might be gained from
tissue co-culture of brain endothelia with astrocytes
(model of BBB) to study the role of platelets in leukocyte
adhesion, transmigration, and other phenomena relevant
to neuroinflammatory diseases.
Meanwhile, recent advances have created more com-
plexity, not simplification. It should be noted that our
knowledge of platelet chemokines and receptors for
them is based largely on murine studies and tissue cul-
ture with limited cell types. For example, human umbili-
cal vein endothelial cells (HUVEC) are widely used
because they are easy to obtain and grow, but they often
exhibit quite different responses compared to brain
micovascular EC, as we have observed in microparticle
studies [65] and pointed out for in vitro studies of anti-
phospholipid antibodies [66]. Endothelial cell (EC) acti-
vation is not a simple yes/no effect but a multi-pathway
Table 3 Platelet surface glycoproteins (GP’s) and agonists
Major Platelet Glycoprotein (GP) Receptors
Classical CD # Integrin Activating Ligand(s)





GP Ia-IIa CD49b a2ß1. Collagen
GP Ic-IIa CD49e a5ß1. Fibronectin
GP Ic-IIa CD49f a6ß1. Laminin
Vitronectin aVß3. Vitronectin, vWF, fibronectin,
fibrinogen, TSP
PECAM-1 CD31 Further interaction with endothelium
P-selectin* CD62P Interaction with leukocytes
* a.k.a. PADGEM or GMP-140 in the older literature.
Listed: Ib, IIa, IIb, IIIa, IIIb (a.k.a. GP IV, CD36), V, IX.
The classical GP designations (which are based on location in electrophoresis)
are given in the first column and the antigen CD numbers in the 2nd column.
The 3rd column gives the newer integrin names, which are compounded of
two subunit types (a, ß). Integrin nomenclature is awkward, hence the
classical names remain in wide use. Many of the GP’s are known also by other
names, e.g. VLA-2, -3, -5, -6 (for “very late antigens”) corresponding
respectively to integrins a2ß1, a3ß1, a5ß1 (or aVß1), and a6ß1. The 4th and last
column gives the ligands which activate platelets via those GP receptors, and
if more than 1 is given, they are in order of potency. For example, the
complex GP Ib-IX is the main site for vWF but it has some activity for other
GP sites, and likewise collagen. In most cases there is evidence of receptor
mobility, clustering, interaction, synergy and inter-dependence, as noted for
Table 4. Data adapted from Table 22.1 and others in Colman et al [10].
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onds of stimulation, such as CD62E cell surface expres-
sion) and slower effects (24-48 hr) that depend on
genetic upregulation of the pathways activated by, for
example, exposure to TNF-a [67,68].
Some unwarranted conclusions about platelet chemo-
kines have been put forth. Geissner suggests [64] that
only platelet CXCL4 (PF4) and CXCL7 are likely to be
important since other cells are richer sources of the
remaining platelet chemokines, and some platelet chemo-
kines are acquired from plasma (Table 6). This implies
that the other platelet chemokines are inconsequential,
and overlooks the fact that platelets are often the first
cells to arrive at a site of vascular injury, and are excep-
tionally responsive to stimuli. Therefore, platelets may
indeed be an important source in the microenvironment
of all chemokines they carry, as has been noted by Baltus
et al for monocyte recruitment [69]. Full discussion of
the platelet chemokine system is beyond the scope of this
review, while our purpose is limited to raising awareness
of the new face of platelet biology. However, to add
dimension, notes on a few of the platelet chemokines fol-
low. Chemokines involved with repair and recovery are
considered in the next section. For surveys of chemo-
kines particularly relevant to MS, see [70,71].
Rantes
This has long been recognized in platelets [60,72]. It was
suspected of being carried on platelet microparticles [73]
and that was subsequently confirmed [74]. Gene poly-
morphisms for this chemokine (CCL5) and one of its
receptors (CCR5) affect the susceptibility, severity, and
age of onset of MS [75]. Ubogu et al found that mono-
nuclear cell migration across an in vitro model of the
BBB was driven by CCL5, being inhibited by antibodies
against it [76,77]. That leukocyte infiltration is driven by
CCL5 gained further support by the clinical and labora-
tory observations of Jalosinski et al [78]. At least one
novel drug is in the pipeline which targets CCR1
(another receptor for CCL5) for therapy of MS and
other inflammatory disorders [79]. Similar findings on
the importance of RANTES are seen in EAE models
[80-83]. This sampler of literature makes clear that
CCL5 is important in MS. However, the participation of
platelets as source of these cytokines is not considered
in these papers, nor are platelets present in the in vitro
studies, though it is clear that platelets are potentially
important players.
Trem
This does not have the structure of a true chemokine
receptor but is included here because of its role in
inflammation. Named as the Triggering Receptor
Expressed on Myeloid cells (TREM), it was discovered
in 2000, was identified on platelets soon after, and is
only recently being understood [84,85]. Initial reports
were that it was pro-inflammatory, then TREM-2 was
identified and appeared to act oppositely (anti-
Table 4 Platelet surface glycoproteins (GP’s) and agonists
Main Platelet Agonists
Agonist Receptor(s) Integrin(s) For GPCR’s:
Strongest Thrombin + collagen
A23187* -
Strong Thrombin PAR1 PAR4 aIIbb3 a2b1
Collagen
PAF
Medium ADP P2Y1 P2Y12 Gqa
TXA2. TP-a,- ß G q G12




Damping Prostacyclins IP R EP2 R
PACAP, VIP VPAC R Gsa
* A23187, calcium ionophore [non-physiological]; admits external calcium.
Listing of the main primary platelet agonists in approximate order of potency, and their receptors types, e.g. PAR = Protease-Activated Receptor. Other
abbreviations are listed below. By “primary” is meant having direct action. For example, fibrinogen and vWF (Table 1) do not bind or activate the normal resting
platelet. The third column lists the integrin names and the last column indicates some which are known to be GPCR’s( =G-Protein Coupled Receptor). Similar
listings appear in many sources. The relative potency may be misleading since it is based on data in vitro whereas in vivo several of these agonists, especially the
“weak” ones, can act synergistically to potentiate or “prime” responses to others [5]. For example, serotonin [266,319]; and vWF-induced aggregation requires co-
stimulation (including by ristocetin, an antibiotic used in laboratory studies) or conformation change of vWF. Information on the GPCR’s is simplified from Ch. 107
of Hoffman et al [8] with terminology updated according to Van Geet et al [320]. The “damping” agonists shown at bottom inhibit activation by raising cAMP
(cyclic AMP) levels, which is opposite the usual effect of cAMP elevation in other cells. These tables are for orientation only. Other abbreviations (see also Table 2):
TXA2 = thromboxane A2; a2A AR = a2A-adrenergic receptor; PACAP = pituitary adenylyl cyclase activating peptide; VIP = vasointestinal peptide; prostacyclins refer
to prostaglandins such as PGE1, PGI2.
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TREM’s act to integrate many kinds of signals, in con-
cert with DAP-12 as a complex. A soluble form also
exists. The main known triggering ligand is the TREM-
Like Transcript 1 (TLT-1), which inhibits thrombin-
induced platelet activation [86], is secreted from platelet
a-granules [87], and modulates neutrophil activation
[88] and probably other leukocytes. Because of its seem-
ing role as a kind of “master integrator” of pro- and
anti-inflammatory signals ("mixed messages”), it is of
great interest in neuroinflammatory conditions such as
MS, as referenced [85]. Here again, the possible contri-
bution of platelets to TREM-mediated events is rarely
mentioned.
Platelet factor 4 (PF4; CXCL4)
PF4 was discovered early (1977) and is secreted in abun-
dance from platelets upon activation. Accordingly, its
measurement has been taken as an index of platelet
activation, such as in MS [54]. As a chemokine, it is
unusual in several ways. It does not exert chemotaxis
for any cell yet tested but a large number of other activ-
ities have been attributed to it (see Table 2 of [63]).
Indeed, the list of actions is so lengthy that some have
doubted the specificity of PF4 effects. A possible solu-
tion to this “embarrassment of riches” is the hypothesis
set forth by Sachais et al [89], that the true function of
PF4 is not specific signaling but is to neutralize electric
charge on glycosaminoglycans (GAG’s ) ,a st h i sc o u l d
well explain the majority of its reported actions.
(Recombinant PF4 reached clinical trials as an alterna-
tive to protamine sulfate for neutralizing heparin [90].)
Clinically, PF4 is best known as the target antigen of
heparin-induced thrombocytopenia (HIT); that is, the
IgG of HIT is directed against PF4, not heparin per se
[91]. Intriguing parallels have been drawn between HIT
and anti-phospholipid syndrome (APS) [92], and
between APS and MS, as we have referenced [66].
Platelet cytokines and growth factors
The cytokines constitute a lengthier list of signaling
molecules, notably including the interleukins, and over-
laps somewhat with the chemokines. Some helpful sum-
mary tables (such as distributed by R&D Systems)
include both groups, and a number of members are
commonly listed in both families, e.g. interleukin 8 (IL-
8) is now CXCL8, and RANTES, once considered a
cytokine, is now assigned as CCL5. Originally, a sharp
distinction was drawn between factors that attracted
leukocytes (chemokines) and factors with other effects
(cytokines, e.g. the interleukins) but that distinction is
increasingly blurry in view of the pleiotropic actions of
so many of these substances.
As the first cells to arrive on the scene of vascular
injury, it makes sense that platelets would be involved
Table 5 Platelet chemokines and receptors
Platelet Chemokines and Receptors
Platelet Chemokine Common Name Receptor(s) Platelet Chemokine Receptors
CXCL1 GRO-a CXCR2>CXCR1 CCR1
CXCL4 PF4 CXCR3B, GAG CCR3
CXCL4L1 PF4alt unknown CCR4
CXCL5 ENA-78 CXCR2 CXCR4
CXCL7 [a] NAP-2 CXCR2>CXCR1 CX3CR1
CXCL8 IL-8 CXCR1, CXCR2
CXCL12 SDF-1a CXCR4
CCL2 MCP-1 CCR2 (Those which are disputed are not shown)
CCL3 MIP-1a CCR1, 2, 3
CCL5 RANTES CCR1, 3, 4, 5
CCL17 TARC CCR4, CCR8
Platelet chemokines and their common names are listed at left, then their receptors, not all of which are present on platelets. Those which are present on
platelets are listed in the right-most column. As noted in text, there is considerable promiscuity of chemokines towards the receptors, some being more specific
than others.
Acronyms for common names of chemokines that activate platelets: CCL17 (TARC): thymus and activating-regulating chemokine; CCL22 (MDC): macrophage-derived
chemokine; CXCL12 (SDF-1): stromal cell-derived factor 1alpha; CCL18 (PARC): pulmonary and activation regulated chemokine.
Table 6 Processing of CXCL7
Processing of CXCL7
pro-PBP pro-Platelet Basic Protein
↓






NAP-2 Most pronounced actions
This shows steps in the processing of CXCL7, which is unusual in having
distinctive activities at each step.
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some of the most informative reviews of platelet cyto-
kines are oriented to the role of platelets in wound heal-
ing [93-95]. One may suspect important roles in
neurological tissue repair as well. The 2008 review by
Nurden’s group [94] includes dozens of factors in addi-
tion to the chemokines listed above. Although no
attempt will be made to list them here, the platelet
“growth factors” include EGF, TGF-b1, -b2, PDGF,
HGF, FGFb (FGF-2), and a series of pro- and anti-
angiogenic factors, e.g., VEGF-A, -C. Platelets also
secrete the antimicrobial peptides known as thromboci-
dins. Of special interest in neurology is the presence of
semaphorin 3A (a.k.a. collapsin-1), another of many
“CNS-specific” agents found in platelets. Also listed in
[94] are the cytokines TRAIL, LIGHT, SDF-1a,H M G B -
1, etc., and the interleukins 1L-8 and IL-6sR in platelets.
Their review misses a few, notably IL-1 from platelets
[96,97], which is secreted on platelet microparticles.
Further discussion of these platelet-derived agents
(which are difficult to neatly classify) is beyond the
scope of this review, our purpose being to bring to
wider attention the astonishing variety of bioactive pla-
telet-derived agents. The following few examples may
not be widely appreciated.
CD40 and CD40 ligand (CD40L, a.k.a. CD154)
Platelets are the main source of CD40L, secreting it to
deliver co-stimulatory signals to antigen-presenting cells
(APC’s) [98-100]. Of note, platelets can induce matura-
tion and activation of dendritic cells (DC) [101,102], but
probably involving more than CD40L alone [103]. The
role of CD40L in MS is well appreciated in reviews
[104,105] and is a target of new therapies [106,107].
Filion et al report that CD40L levels on monocytes were
highest in secondary progressive MS (SPMS) [108].
Harp et al demonstrated that CD40L/IL-4 as well as
another stimulating reagent induced B cells to upregu-
late CD80 and HLA-DR; however, only CD40L/IL-4 was
effective in eliciting CNS-antigen specific proliferation
by autologous T cells [109]. CD40L is perhaps best
known for other putative actions which make it a risk
factor in cardiovascular disease [110], although some-
what controversially.
An important technical issue arises with CD40L. Prior
to about 2005, and often yet today, circulating levels of
CD40L were measured in serum by standard ELISA kits.
We reported in 2004 [111] that serum levels are largely
an artifact of platelet activation during blood clotting,
being from 10-fold to 50-fold higher than in plasma spe-
cimens. This was subsequently confirmed by at least two
other groups, and the kit makers have since changed
their instructions to advise use of plasma, not serum for
assay. In view of this, one must question the significance
of reports based on serum assays, since serum levels
reflect the total releasable platelet CD40L, not the true
plasma level. It appears that this is not yet fully appre-
ciated since several reviews make no mention of it and
accept earlier reports on the same footing as more
recent studies that measure plasma levels. Moreover,
one may expect similar artifacts for other chemokines
secreted from platelets if measured in serum, especially
PF4, but also the others since nearly all will be released
to serum as an artifact of clotting, inflating true plasma
levels.
Toll-like receptors on platelets
The discovery of toll-like receptors (TLRs) on platelets
in 2004 was another completely unexpected develop-
ment. Other immune functions of platelets had been
earlier noted, including generation of killer-like reactive
oxygen species (ROS) [13], phagocytic activity, secretable
antimicrobials (thrombocidins), interactions with leuko-
cytes and endothelial cells by direct contact or secretory
signaling, and as the principal source of CD40L
(CD154) [100,110].
F i r s td i s c o v e r e di nt h ef r u i tf l y ,a b o u tad o z e nT L R ’s
are now known and each is tuned to recognize a distinct
class of pathogen-associated molecular patterns
(PAMP’s). The PAMP’s which are recognized include
bacterial components such as flagellin, lipopolysacchar-
ide (LPS), lipoproteins, peptidoglycans, certain regions
o fD N A ,a n ds oo n .T h et r u eT L R ’s are transmembrane
surface proteins, but proteins with similar PAMP-recog-
nition functions for virions occur in the cytoplasm
[112,113]. The membrane TLR’s, some of which func-
tion as heterodimers (e.g. TLR2 plus TLR1 or TLR6),
upon engagement with ligand, pass their signals through
a series of accessory transducers to the cell nucleus
where antimicrobial genes are activated to yield pro-
d u c t ss u c ha sI L - 1a n dT N F - a. Since platelets lack
nuclei, however, they seemed irrelevant to studies of the
tissue distribution of TLR’s.
To our knowledge, it was Shiraki et al who discovered
the first TLR’s in platelets, TLR1 and TLR6, by mRNA,
Western blotting, and flow cytometry [114]. Further-
more, their expression was upregulated in response to
IFN-g. The next year, Cognasse et al reported also
TLR2, TLR4, and TLR9 on platelets [115], and observed
that expression levels increased two-fold upon platelet
activation. More recently, the latter authors have fol-
lowed up with further insights on platelet TLR’s, and
propose a major and unique role of platelets in bridging
innate to adaptive immunity on this basis [116,117].
These findings add a new dimension to studies of
TLR’s in neuroinflammatory conditions. For example,
the study by Chearwae and Bright of TLR4 and TLR9 in
a model of MS documented upregulation of these recep-
tors in T cells after induction of EAE, and favorable
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prostaglandin and curcumin treatment [118]. However,
now that platelets are known to also possess these
receptors, it appears that their participation in such pro-
cesses deserves consideration in future experiments of
that kind.
Peroxisome proliferator-activated receptors
Peroxisome proliferator-activated receptors (PPAR’s), of
which three are known, are ligand-activated nuclear
transcription factors of the hormone receptor superfam-
ily. They are widely disseminated and appear to function
chiefly in regulating metabolism, notably of fats, and
this fact has elevated the fibrate drugs (agonists of
PPAR) to a level of importance second only to the sta-
tins for prevention and treatment of coronary artery dis-
ease. However, like the statins, they seem to have
“pleiotropic” effects, prominently including anti-inflam-
matory actions now under investigation for treatment of
MS [119-121]. Indeed, the role of PPAR’s in CNS disor-
ders is of much current interest [122,123], with promise
of applications in Parkinson’sa n dA l z h e i m e r ’sd i s e a s e s
among others [124,125]. Yang et al has reported on
PPARa regulation of immunity and the EAE model of
MS [126]. PPAR’s appear to be an important target of
the NSAID’s [127]. Interestingly, it appears that lysopho-
phatidic acid (LPA) is a natural activator of PPAR [128],
and that agonists of endocannabinoid receptors also sti-
mulate PPAR in a model of MS [129]. Importantly for
MS, PPAR appears to control inflammation induced by
CD4+ T cell infiltration, at least in vitro [130].
Since platelets lack nuclei they are not expected to
have PPAR’s, but platelets are full of surprises. Both
PPARb/δ and PPARg were found expressed in platelets
[131]. Furthermore, the same authors have demon-
s t r a t e dt h a tP P A R g is released from activated platelets
on microparticles (PMP), which is taken up by promo-
nocytic cell line in tissue culture; and that agonists of
PPARg induced platelet release as judged by secretion of
sCD40L and thromboxane A2 (TxA2) [131]. Although
the full implications of these late findings remains to be
seen, they are paralleled by other developments in PPAR
research, such as the recognition that active PPAR is not
necessarily confined to the surface of the nucleus. The
therapeutic potential of agonists of PPAR, such as rosi-
glitazone (Avandia™) and pioglitazone (Actos™)f o r
PPARg, needs further study but it has been shown that
they inhibit platelet release of CD40L [131].
Platelet-derived bioactive lipids
Recognition that certain lipids perform critical signaling
functions began in the 1970’s with the observation that
human semen caused contraction of uterine muscle
strips, leading to identification of the prostaglandins,s o
called for that reason. Related families of active lipids,
such as the leukotrienes and thromboxanes, subse-
quently came to light and are collectively known as the
eicosanoids, for the 18-carbon arachidonic acid precur-
sor in the cell membrane. From the outset, platelets
were seen as a major source of these agents. Indeed, a
common measure of platelet activation today is the cir-
culating level of thromboxane B2 (TXB2), the stable
breakdown product of thromboxane A2 (TXA2, half-life
30 sec’s). That early work culminated in understanding
the mechanism of aspirin and led to development of the
other COX inhibitors and NSAID’s, most of which inhi-
bit platelet activation. Since that work is well-known, we
shall limit discussion to brief review of some of the
more interesting recent developments relevant to the
link between platelets and neuro-inflammatory diseases.
Several recent reviews are available on the general sub-
ject of bioactive lipids [132] and with emphasis on the
neuronal nucleus [133].
Lysophosphatidic acid (LPA) and sphingosisine-1-
phosphate (S1P)
The emerging significance of LPA in medicine has been
reviewed [134,135] and with focus on autoimmune [136]
and neurological diseases [137]. Its sphingolipid homo-
log, S1P, will not be reviewed here because it is well-
k n o w nt on e u r o l o g i s t sa st h etarget of FTY720 (fingoli-
mod), a pro-drug that antagonizes the S1P receptor(s)
to limit leukocyte migration for treatment of MS
[138,139].
LPA is formed mainly by the enzyme, autotaxin [a.k.a.
lysophospholipase D (lysoPLD)], which is secreted by
platelets and other cells and is inhibited by LPA
[140,141]. Most authors accept platelets as the main
source of plasma LPA, and this is supported by a study
of the effect of aspirin in cerebral vascular disease:
aspirin treatment reduced LPA levels, which rose again
when aspirin was stopped, leading the authors to con-
clude that platelet activation is the major source of LPA
[142]. LPA can also be formed by mild oxidation of
low-density lipoprotein (LDL) [143]. Of the several
known LPA receptors, LPA (5) is established for plate-
lets, is highly selective, and may be centrally involved in
platelet activation [144].
LPA alone appears to be a weak agonist of platelets
but its potency is increased synergistically by the pre-
sence of other lysolipids [145]. Similarly, Eriksson et al
found synergy of epinephrine with LPA in inducing
adhesion of platelets to an albumin-coated surface [146].
The study of Kang et al [145] documents augmented
production of CXCL16, a regulator of T cell migration,
by macrophages due to presence of LPA (or S1P) fol-
lowing stimulation by LPS, of interest in MS because of
parallels with S1P. Also of interest vis a vis MS is invol-
vement of LPA in lymphocyte-endothelial interaction in
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function [135]. It is reported that PPARg is an important
target of LPA [141], wherefore those authors are devel-
oping inhibitors of the LPA receptor. It has been con-
vincingly shown that LPA is also involved in the
regulation of blood pressure [148].
Lin et al showed that LPA stimulated expression of
IL-8 and monocyte chemo-attractant protein-1 (MCP-1)
in endothelial cells, in a manner that depended on IL-1
[149]. It is not widely appreciated that platelets are an
important source of IL-1, particularly in a localized
micro-environment [150]. Several studies have found
potentially important links between platelet-derived LPA
and cancer metastasis [151,152].
Interestingly, it has been found that human platelet
responses to LPA depend strongly on individual donors
[153], classified by those authors as “responders” and
“non-responders”, and leading them to propose a novel
inhibitory pathway in the ≈20% of non-responsive sub-
jects. Another group also reported variations in observed
effects depending on donor [146]. In assembling this
review we noted some apparent conflicts on the
reported action of LPA on human platelets, which are
probably resolved in part by donor differences. Indeed,
it was reported that in mice, LPA markedly inhibited
platelet activation, induced a bleeding diathesis, and
attenuated thrombosis [140]. Such opposite effects may
be explained by alternative receptors [154] but the
details are obviously complicated and poorly under-
stood. Much remains to be clarified about the role of
LPA in hemostasis and thrombosis, and in its many
other putative roles in health and disease.
Endocannabinoids
The endocannabinoids, such as 2-arachidonyl glycerol
(2-AG), are lipid mediators discovered in 1995 which
have recently shown promise against neuroinflammatory
disorders, as in the virus EAE model of MS of Loria et
al [155]. Mechanisms of this benefit are said to include
activation of PPAR. With specific regard to platelets, a
key enzyme involved was purified from platelets and
studied [156], more recently in further detail [157].
There is no doubt that 2-AG can be produced by plate-
lets, and that 2-AG induces platelet activation [158] but
it is not yet clear if platelets possess one of the two
receptors for 2-AG, dubbed CB(1) and CB(2), since
those authors found no evidence for this receptor on
platelets whereas Schafer et al found that a specific
antagonist of CB(1), rimonabant, blocked the effect of 2-
AG [159].
Lipoxins; resolvins, protectins
These lipid mediators of inflammation are recently iden-
tified. The extent to which platelets contribute them has
not (to our knowledge) been much studied but the fact
that they are sensitive to aspirin [160] suggests platelets
as a significant source, i.e., platelets are major players in
the “inflammatory hypothesis” of cardiovascular disease
[161]. The resolvins are named for their role in resolving
inflammation. Being derived from omega-3 fatty acids
via the lipoxygenase (LOX) pathway, this may offer a
rational basis for the cardiovascular benefits of polyun-
saturated fatty acids (PUFA’s) [160,162,163]. Resolvins
have been shown to inhibit reperfusion brain injury, and
the brain lipid messenger, 10,17S-docosatriene, potently
inhibited leukocyte infiltration and other negative mea-
sures [164]. Resolvin E1, derived from omega-3 eicosa
fatty acid, inhibited platelets in an agonist-specific man-
ner, reduced leukocyte rolling in venules of mice, and
modulated expression of several adhesins in monocytes
and neutrophils, possibly accounting for some of the
benefits of dietary PUFA’s [165]. Further work may lead
to important new insights on lipid mediators in neuro-
degenerative diseases and their possible relationship to
platelet activation [166-169].
Platelet activating factor (PAF)
PAF is named for its potent activation of platelets, with
effects down to picomolar concentrations [170]. It was
discovered in the late 1970’s by its strong anaphylactoid
a c t i o n ,d i s t i n c tf r o mt h a to fc o m p l e m e n tC 3 a ,C 5 a
[171], and was found to be a potent chemotactic stimu-
lus for inflammatory cells [172,173]. Its biochemistry
was well described by Braquet [174], who also described
some synthetic inhibitors of it intended as drug candi-
dates, and the natural inhibitors from the plant, Gingko
biloba,k n o w na sginkgolides [175]. In vivo, PAF is
rapidly broken down by a specific acetylhydrolase, PAF-
AH. Although not an eicosanoid, most PAF derives
f r o mt h es a m ee n z y m es y s t e m .I n h i b i t o r so fp h o s p h o l i -
pase A2, the rate-limiting step in the main route of PAF
production, is under investigation as a drug target [176].
In EAE, elevated PAF in the spinal cord, which was not
the result of reduced PAF-AH activity, appeared to be
caused by cytosolic PLA2 activity [177]. For broader
review of PAF as drug target, including for application
to MS, see [178].
Evidence for PAF transport on platelet-derived micro-
particles (PMP) was reported [179], and more recently,
the enzyme which degrades it, PAF-AH, was also identi-
fied on PMP [180]. PAF also circulates bound to plasma
lipoproteins [181], is stabilized by albumin, and can be
produced by many cells. Platelet activation induced by
co-incubation with neutrophils stimulated by fMLP
(fMLP stands for formyl-Met-Leu-Phe) was almost com-
pletely prevented by PAFR blockade; and the PAF
released in the interaction was greater than the sum
produced by platelets or neutrophils alone [182]. The
explanation was that platelets secreted an inactive form
of PAF (de-acetylated) which was re-acetylated by the
neutrophils and then thrown back to strongly activate
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esis of the role of platelets in diseases such as MS: that
platelets are active partners with leukocytes in their
entry to the CNS. More specifically, the PAF secreted by
the cooperation of platelets and leukocytes would facili-
tate opening the BBB in the microenvironment, since
one of the most prominent actions of PAF is disruption
of endothelial junctions [183-186].
Among the unexpected “pleiotropic” benefits of the
statin drugs appears to be protection against neuronal
d a m a g ec a u s e db yP A F[ 1 8 7 ] .I tm a yb er e l e v a n tt h a t
statin drugs have also been shown to inhibit release of
endothelial microparticles [188], and this may apply also
to platelet microparticles insofar as platelets have the
same pathway of microparticle production.
A study of Japanese MS patients found that the PAF
degrading enzyme, PAF-AH, was significantly lower in the
patients [189] but this was not reflected in the genotype.
On the other hand, the same group studied PAF receptor
(PAFR) gene polymorphisms in MS and found significant
differences compared to controls, concluding that this
gene is a susceptibility factor for MS [190]. A gene micro-
array analysis of MS lesions revealed that transcripts for
PAFR were among those elevated in chronic/silent pla-
ques, as were the platelet-specific glycoproteins IIb and
IIIa [191]. A few years later, Kihara et al reported that in
an EAE model of MS, levels of mRNA for the PAF recep-
tor (PAFR) in murine spinal fluid correlated with disease
activity, and that knock-out of the PAFR gene resulted in
lower incidence and abrogated severity of symptoms [192].
In earlier work, Callea et al reported 6-fold elevated PAF
in the plasma of human RRMS patients and 15-fold eleva-
tion above controls in CSF [193]. Levels correlated with
radiographic findings. The PAF subtype differed between
plasma and CSF, indicating “different cellular origins” in
the two compartments [193].
PAF can cause thrombocytopenia at levels as low as 3
ng/kg [194]. Mild thrombocytopenia is sometimes
reported for MS patients (see later) and is possibly a signa-
ture of PAF activity. A role for PAF in stroke and brain
injury has long been suspected [195]. Blockade of PAFR
substantially reduced leukocyte adhesion to endothelia of
hamster cheek pouch vessels following ischemia and
reperfusion [196].Osborn et al explored the protective
action of plasma gelsolin on lipid mediators and found
that it modestly but significantly (p < 0.0001) inhibited
LPA-induced platelet activation, but markedly inhibited
PAF-induced platelet activation (>75% inhibition) at phy-
siological gelsolin concentrations [197]. Thus, gelsolin may
be an important natural modulator of PAF activity; plasma
gelsolin is often reduced in association with disease [197].
Others
This review provides only a sampler of agents of interest
in each category. Several other classes of lipid mediators
relevant to platelets in neuroinflammation are covered
in the reviews cited earlier, e.g. the several phosphatidyl
inositol phosphates (PIP’s), sphingosines, and the recent
discovery of the importance of palmitoylation. Of closely
related interest are the many phospholipases whose
activities govern most lipid mediators.
Inflammatory agents of the coagulation system
In the last decade it has come to attention that several
of the coagulation proteins are inflammatory or anti-
inflammatory, and these are relevant to neurodegenera-
tive diseases because they are implicated in MS (see
later). They relate to platelets since the two systems go
hand-in-hand: Activated coagulation stimulates platelets
(e.g., thrombin) and activated platelets amplify
coagulation.
Fibrinogen
The emergence of fibrinogen as a potent neuroinflam-
matory mediator has been a surprise [198,199]. It has
been identified in lesions of MS patients, as referenced
in following sections.
The protein C system
The protein C system acts to curtail thrombin genera-
tion, mainly by inactivation of activated FV, but is rather
complicated owing to cofactors such as protein S, pro-
tein C inhibitor, thrombomodulin, the endothelial pro-
tein C receptor (EPCR), and other complexities [200].
Protein C itself is a vitamin K-dependent PL-binding
protein, meaning that it can exert its function on acti-
vated platelets, but also on the endothelium via EPCR.
Perhaps the most spectacular demonstration of its anti-
inflammatory potential was the discovery that activated
protein C (aPC) is an effective therapy for sepsis,
regarded as a severe inflammatory state [201,202]. This
is remarkable in view of the decades of failed efforts to
treat sepsis. The anti-inflammatory efficacy of aPC
appears to be largely independent of its anti-coagulant
action. The use of aPC in MS has been little investi-
gated, but proteomic analysis of MS lesions revealed
protein C inhibitor [203], leading those authors to
demonstrate substantial benefits of aPC in the EAE
model of MS. Genc had previously made a good case
for such investigations, citing relevant literature [204].
Thrombomodulin was also effective in an animal model
of inflammation induced by lipopolysaccharide (LPS)
[205].
Contact proteins
The kinin-kininogen system (KKS) is most familiar for
instigating the contact (or intrinsic) coagulation cascade
[206] and participating in platelet aggregation [207]. Its
components are known inflammatory mediators [208].
Of direct relevance to MS, it was recently shown that a
kinin receptor is pivotal to T leukocyte recruitment to
the CNS [209]. The KKS system overlaps somewhat
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specialist in the KKS system [210], it came to light
through investigations of snake bites, leading to the dis-
covery of the vasoactive nonapeptide, bradykinin,
released by cleavage of high-molecular weight kininogen
(HMWK, a.k.a. HK). Bradykinin is a main target of the
widely prescribed ACE inhibitors, which are proving to
have unexpected neuroprotective effects, i.e. indepen-
dent of blood pressure [211]. With regard to the role of
platelets in the above-cited study [209], it has been
shown that platelet-leukocyte interaction can occur via
HMWK bridging from platelet GP 1ba to the CD11b/
CD18 complex (Mac-1) on leukocytes [212]. The more
conventional mode of interaction is between P-selectin
of platelets and P-selectin glycoprotein ligand-1 (PSGL-
1, CD162) on leukocytes, which can be effectively
blocked by antibodies to the sialyl Lewis
x antigen [43].
Interestingly, PSGL-1 was recently reported to be the
means of entry of the neurotropic enterovirus 71, and
probably other neuropathic viruses of the same family
[213], but those authors do not offer insight on how it
then gains access to the CNS. In view of the foregoing,
a possible role for platelets warrants consideration.
Thrombin
Lastly, thrombin itself has long been recognized for its
inflammatory actions, recently extended by the finding
that it is required to initiate CCR2-dependent leukocyte
recruitment, and that it is “the principal determinant of
the outcome after vascular injury” in several animal
models (LPS-induced endotoxemia, antibody-mediated
graft rejection, carotid artery ligation) [214].
Platelets and complement
The complement (C) system is a humoral arm of the
innate immune system and can attack self-cells when
marked by autoantibodies or due to defects in proteins
that protect against C. It is a complicated system of cir-
culating proteins, analogous to the coagulation system
in that its activation involves a series or cascade of pro-
teolytic conversions of zymogens to their active forms,
resulting in several ultimate products, notably, the C5b-
9 membrane attack complex which kills by punching
holes in the target cell. The C system has several links
to the coagulation system [215,216]. For example, pro-
tein S, a cofactor of the protein C system, is carried in
circulation largely bound to C4 binding protein (C4bp),
a complement component. It is well known that C is
central to the pathology of many autoimmune and
inflammatory disorders.
Platelets possess C receptors CR2, CR3, CR4, C1q, C1-
inhibitor, and factors D, and H. Others are listed in
some sources but are disputed as they may be acquired
from plasma. Platelets are capable of deploying the
lethal C5b-9 complex [217]. In addition, like other
blood cells, platelets contain a set of membrane proteins
which specifically protect them against autologous C-
mediated attack, i.e. against self-injury by C [218]. These
are CD55 (decay accelerating factor, DAF), CD59 (mem-
brane inhibitor of reactive lysis, MIRL), and homologous
restriction factor (HRF) [219,220]. Morgan mentions
others less well defined. Recently, another such protec-
tive protein, Crry, was identified in murine platelets and
erythrocytes [221,222], later extended by those authors
to work on leukocytes [223], but Crry appears to be
absent in humans. Defects in these proteins can result
in pathology, e.g. paroxysmal nocturnal hemoglobinuria
(PNH). We investigated CD59 on platelets from PNH
patients and found levels ≈10% of normal, but findings
on altered sensitivity to C-mediated lysis were inconclu-
sive [224].
A recent finding of significance in neurology is that
platelet-bound complement fragment, C4d, is a highly
specific biomarker for systemic lupus erythematosus
(SLE) and neuropsychiatric lupus [225]. Those authors
propose this as a biomarker of cerebrovascular inflam-
mation generally. Moreover, it correlated closely with
positive lupus anticoagulant (LA) (p < 0.0001), and less
well with positive anti-cardiolipin (aCL) (p = 0.035)
[225]. Work by the same authors demonstrated that pla-
telet-bound C4d was associated with ischemic stroke
[226]. We have drawn attention to evidence for C-
mediated injury in the neuropsychiatric aspect of anti-
phospholipid syndrome, which can resemble MS, as
referenced [66]. According to Roach et al, C5a signaling
in macrophages is synergistic with PAF and with LPA
[227].
Despite the presence of the above mentioned protec-
tive proteins, platelets are very sensitive to C-mediated
attack. We have witnessed the serum-dependent frag-
mentation of platelets into microparticles when opso-
nized with an anti-platelet IgM [228]. However, platelets
are not entirely defenseless against C, as it has been
shown that attack complexes are selectively shed from
the platelet membrane on platelet microparticles (PMP),
allowing recovery of the parent cell [229,230]. Butikofer
et al has shown that the microparticles released from
erythrocytes are selectively enriched in proteins that
protect against autologous C, at the expense of these
proteins in the parent cell, and in their discussion cite
evidence that same is true of platelets [231]. This
implies that microparticle shedding sensitizes the rem-
nant cell to C-mediated injury.
New methods are expanding the inventory of
platelet constituents
The list of active agents in platelets has been expanding
in recent years by application of new technologies: pro-
teomics, lipidomics, and mRNA transcript analysis.
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were not identified – in the supernatant of activated pla-
telets [232-234]. Some 578 proteins were identified just
in platelet microparticles [235]. Several proteomic stu-
dies of the whole platelet membrane were recently
reviewed [236], with a special section devoted to pro-
teins of the lipid rafts. (Lipid rafts are regions of the
membrane which resist detergent solubilization and play
critical roles in platelet physiology [237,238]). Raft
regions are selectively shed with microparticles, e.g.
[239].
The platelet “transcriptome” is also growing. Although
platelets lack nuclei, thousands of transcripts have been
identified in platelets, including coding for enzymes,
interleukin receptors, etc., many of which were pre-
viously unknown in platelets, e.g. PEAR-1 [240-242].
Some of the same leaders in the field have sought to
extend proteomic studies to include platelet-specific
genes [243]. A recent paper claims to show that nuclear
factor NFkB is not only present in platelet but active
[244], which seems impossible since NFkB is a nuclear
transcription factor, as discussed in an editorial [245].
The still-nascent field of lipidomics, which applies the
same methods as proteomics (mass spectrometry) but to
lipids, promises great advances in sorting out the myriad
of bioactive lipids. Potentially important new platelet
proteins continue to come to light, such as the septins,
reviewed in relation to neurodegenerative disorders
[246], and the vanilloid receptor (TRPV1) for noxious
stimuli such as capsaicin [247] but also for several cate-
chol amine metabolites such as homovanillic acid [248].
We shall cite the significance of some of this work to
MS presently.
Serotonin: a platelet-neuron nexus?
In 1985, Stahl pointed out a number of parallels
between platelets and neurons, with focus on the storage
and secretion of serotonin (5-HT), and the similar sensi-
tivities to many CNS-activ ed r u g s[ 2 4 9 ] .R e e de ta l
devoted a section of their review of mechanisms of pla-
telet secretion to a comparison with vesicle trafficking
in neurons [250], echoing work by Lemons et al [251].
Steidl et al in a study of CD34+ hematopoietic progeni-
tor cells identified numerous ion channels, neuromedia-
tors, and other proteins previously assumed to be
restricted to the CNS [252]. The reason for abundant
acetylcholinesterase activity of erythrocytes (but not pla-
telets [253]) remains a mystery attracting much interest
[254-257]. The above-mentioned finding of endocanna-
binoid receptors, semaphorin A, monoamine oxidase
(MAO), etc., on platelets is more of the same.
Serotonin (5HT) does not itself cross the BBB but
some of its metabolites or precursors do, resulting in a
degree of correlation between peripheral and CNS levels
of 5HT [258]. Platelets are the main source of circulat-
ing 5HT but arteries and veins can act as reservoirs
[259]. Of the several receptors for 5HT, platelets possess
5HT(1), as well as a serotonin transporter (SERT).
Among the more surprising recent discoveries is the
role of 5HT in regulating bone density [260].
Of direct relevance to inflammation is the demonstra-
tion that 5HT enhanced monocyte stimulation of CD4+
T cells and cytokine production following LPS exposure
[261]. That paper also reports increased plasma 5HT in
Alzheimer’s disease (AlzD), which correlated with dis-
ability index [261]. Ciz et al reported inhibition of the
oxidative burst of phagocytes by 5HT, via action on the
5HT receptor and on myeloperoxidase activity [262].
Treatment of MS with selective serotonin reuptake
inhibitors (SSRI’s) was reportedly very promising [263].
Plasma levels of 5HT are governed mainly by the num-
ber of SERT’s on the platelet, with more or less of them
appearing at the membrane surface depending on exter-
nal 5HT concentration [264]. Accordingly, the number
of SERT’s per platelet is sensitive to SSRI’s. Platelet
SERT density correlated closely with P-selectin expres-
sion, a marker of platelet activation and cell-cell interac-
tion, consistent with the concept of 5HT as a weak
agonist [265]. However, Galan et al concluded that, con-
trary to tradition, 5HT is not a weak agonist of platelets,
but instead sensitizes them or potentiates their respon-
siveness [266].
Abdellah et al observed significant differences in the
action of SSRI on platelets, depending on polymorph-
isms of the gene for SERT (SLC6A4) and its promoter
(5-HTTLPR) [267]. In an EAE model, it was found that
knock-out of SERT caused increased plasma 5HT and
attenuated symptoms, with effects most pronounced in
female animals [268]. Interestingly, a strong gender
effect was seen also with the influence of cannabinoids
(in habitual cannabis smokers with cognitive impair-
ment) on 5HT uptake in plasma [269]. In MS, levels of
5HT in CSF appear to correlate well with progression of
disease [270]. Norepinephrine, at plasma levels seen in
stress disorders, desensitizes the 5HT(1) receptor by
uncoupling it from SERT via G proteins, leading the
authors to conclude that NE can modulate 5HT
responses and the action of SSRI’s [271].
It was recently shown that 5HT can become cova-
lently bound to a number of proteins, a process termed
seritonylation, including to small GTPase’s, with roles at
the vessel wall [272] and in platelet activation [273].
The latter authors report that low levels of plasma 5HT
markedly prolong the bleeding time. In summary, these
brief notes from a large literature suggest that 5HT
from platelets, or acting on platelets, may be a signifi-
cant factor in neuroinflammatory conditions, especially
in a restricted microenvironment such as at the BBB.
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tangles
Although the focus of this review has been on MS, many
of the papers cited refer also to other neuroinflammatory
disorders. Here we take the example of Alzheimer’s disease
(AlzD). In 1998, we reported chronic platelet activation in
AlzD [274] but that work was largely ignored in the blind-
ing light of the b-amyloid hypothesis. Several recent devel-
opments are now forcing a “radical rethink” of the disease.
(i) Platelet activation in AlzD has been confirmed [275].
Levels of homocysteine, considered a marker of hypercoa-
gulable state, also impact on AlzD [276]. (ii) Two recent
large genetic studies uncovered, in addition to APOE,
three other AlzD-related genes, notably clusterin and CR1,
both signatures of complement involvement [277,278]. (iii)
Mounting evidence indicates that AlzD is inflammatory in
nature and etiology [279], and that it can be controlled by
exercise [280] and possibly diet [281]. (iv) Consistent with
an inflammatory vascular etiology is the presence of com-
plement fragment C1q in the brain lesions of a mouse
model [282] and of the coagulation protein, fibrinogen, in
human AlzD plaque [283]. (v) The hypothesis that age-
related cognitive decline generally is mainly a vascular con-
dition is supported by finding that retinal microvascular
abnormalities predict decline [284]. (vi) To the extent that
b-amyloid is truly causative, it should be noted that plate-
lets are the principal source of amyloid precursor protein
(APP) [285,286]. However, the relation of plasma levels of
b-amyloid forms to AlzD has been controversial, and ratios
of some of the forms are associated as much with vascular
dementia as with AlzD [287]. In this connection, it is rele-
vant to note that platelets appear to be responsible for
post-surgical cognitive impairment [288].
Finally, (vii) recent work linking all of the above into
one coherent hypothesis was brought to our attention
during peer review of this paper: Platelets are now
strongly implicated in the overexpression of the enzyme
which liberates the offending peptide, amyloid-b (Ab),
from APP, known as BACE (b-site APP Cleaving
Enzyme), or generically, “b-secretase”.B A C Ew a sf i r s t
identified as the long-sought b-secretase in 1999 [289]
but those authors did not assay platelets in their study
of its tissue distribution. In 2004, a direct relation was
found between early-stage AlzD and platelet activity of
BACE, as well as ADAM10, leading those authors to
propose this assay as a diagnostic aid [290]. (ADAM10,
also on platelets, has similar activity [291]). This was
confirmed in 2005 [292] and again in 2008 [293]. BACE
inhibitors to protect against progression of AlzD are in
active development, but Hu et al advise caution because
of their finding that BACE inhibition also delays (but
does not totally abolish) remyelination by blocking clea-
vage of neuroregulins [294]. Interestingly, it was recently
shown that platelet membrane cholesterol content mod-
ulates the activity of b-secretase, possibly explaining
reported relations between cholesterol, dietary lipids,
and AlzD [295].
Platelets in multiple sclerosis: smoking gun?
MS is an immune-mediated demyelinating disease of the
CNS and can be regarded as a model neuroinflamma-
tory condition. Like most other autoimmune disorders,
the etiology and pathophysiology of MS remains uncer-
tain but most agree that a combination of genetic and
environmental factors are required to initiate an
immune reaction against CNS antigens. For example,
Gong et al [296] has proposed a 5HT deficiency at high
latitudes as a predisposing factor in the epidemiology.
The possible involvement of platelets in MS was first
studied by Putnam in 1935, who considered a role for
venule thrombosis in CNS demyelination [297]. In the
1950’s-60’s, at least ten studies appeared on the relation
of platelets to CNS demyelination, several of which
reported augmented platelet adhesiveness in MS, which
correlated with disease activity [298-301]. More recently,
a number of observations of platelet abnormalities in
MS patients have appeared [302-304], and others cited
below. We became interested when colleague W. Shere-
mata encountered MS patients with severe immune
thrombocytopenic purpura (ITP) [305], leading to our
report of increased platelet microparticles and platelet
activation marker CD62P (P-Selectin) in MS [306].
Thus, chronic platelet activation in MS may now be
regarded as well established, including by the report of
Cananzi et al cited earlier [54]. Epidemiological studies
have found a prevalence of ITP-like thrombocytopenia
in MS patients about 25-fold higher than in the general
population [304,307]. As earlier mentioned, mild throm-
bocytopenia, which could often be overlooked as insig-
nificant, could be a signature of PAF activity.
It may be objected that a modest degree of platelet acti-
vation in MS is simply a consequence of general inflam-
mation. However, the finding of platelet-specific GP IIb/
IIIa in lesions of MS patients [191] comes close to
“Smoking-Gun” evidence of platelet involvement. Relat-
edly, several elements of coagulation have been detected
in the lesions including fibrin, tissue factor (TF), and pro-
tein C, suggestive of a procoagulant state [191,203].
For these and other reasons, MS has been described as
a vascular disease [308]. The adhesion molecule,
PECAM-1, may be particularly important in this regard.
It was reported in 1999 that levels of serum soluble
PECAM-1 (sPECAM-1) are significantly elevated in
patients with active, gadolinium-enhancing lesions [309].
In 2001, we reported that PECAM-1-positive endothelial
microparticles (EMP) are elevated in MS patients only
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enhancing lesions [310]. In 2005, another study docu-
mented increased sPECAM-1 during acute relapse and
in remission compared with progression [311]. It is not
clear if the microparticle-bound form is functionally dis-
tinct from the soluble form but we have discussed
examples of “soluble” biomarkers which are in fact
membrane particle-bound [52] (Part D). These and
other findings suggest that PECAM-1, whether soluble
or MP-bound, may be at least an indicator of BBB dis-
ruption in MS and a biomarker of disease activity, and
probably a key participant. The PECAM-1 gene is
located on chromosome 17 in the region 17q23 [312]
and, given that the region 17q22 was proposed to be an
MS-susceptibility factor, PECAM-1 seemed to be a good
candidate gene. However, at least two studies failed to
find convincing support for that hypothesis [313,314].
Our findings, together with evidence reviewed in prior
sections, suggest a broader hypothesis, namely, that pla-
telet interaction with leukocytes at the endothelium of
the BBB is responsible for the release of PECAM-1 to
the circulation, and associated infiltration of leukocytes.
Platelets are capable of directly activating both lympho-
cytes and dendritic cells [103,315]. In addition, it is
tempting to postulate involvement of platelet activating
factor (PAF) in view of its potency at disrupting
endothelial junctions, and likely signature of thrombocy-
topenia (see Section 9). Elevation of PAF in the CSF and
plasma of RRMS patients was reported, and the authors
concluded that PAF is likely responsible for the early
disruption of the BBB in MS [193]. Moreover, PAF
receptors are up-regulated in MS lesions [191].
Differences in these parameters between RRMS and
progressive MS have been noted in several reports, hint-
ing at distinctive pathophysiologic pathways. Humm et
al observed such differences in responses to prednisone
[316]; and PAF activity was higher in RRMS than in sec-
ondary progressive MS [193]; and stronger differences
were observed in sP-Selectin and other markers in
RRMS compared to secondary progressive [311].
As earlier mentioned (Section 9), PAF is inactivated by
PAF-AH but no association of the inactivating mutation
of the PAF-AH gene with RRMS or progressive MS was
found [189]. Nevertheless, the PAF-AH activities in MS
were significantly lower than in healthy controls [189].
Such a decrease of PAF-AH activity may in part be
responsible for the reported increase of PAF in MS
plasma and CSF, and therefore could contribute to the
inflammation and vascular permeability changes seen in
the CNS of MS. On the other hand, a small Japanese
study did find a significant association between MS sus-
ceptibility and a PAFR polymorphism causing a modest
but significant reduction of PAF-dependent signaling
[190].
We also found that platelet-associated IgM (but not
IgG) is increased in MS patients [317]. We feel that this
is of potential importance to understanding the patho-
physiology of MS. However, present knowledge of anti-
phospholipid antibodies is too fragmentary to offer
much insight on the significance of this finding, as dis-
cussed [66].
In summary, there are numerous mechanisms by
which platelets could substantially contribute to the
pathophysiology of MS. We do not pretend to have any
specific hypothesis, nor do we propose that some bizarre
platelet abnormality actually causes MS (although that is
not impossible). Rather, the purpose of this review is to
call attention to the neglected platelet and its potential
to modulate inflammatory processes.
Summary and conclusions
This review indicates that platelets could be pivotally
involved with neurodegenerative and autoimmune con-
ditions. At present, the potential role of platelets in such
disorders has been neglected, although well appreciated
in the cardiovascular and cancer research fields. The
majority of studies in tissue culture designed to eluci-
date the pathophysiology of neurodegenerative diseases
such as MS have investigated interactions of leukocyte
subsets and endothelial cells, but it is likely that these
interactions could be significantly modulated in the pre-
sence of platelets from patients vs. healthy controls.
The question may arise, exactly what kind of hypoth-
esis could link platelets to such a wide variety of neuro-
logical conditions? Our view is that platelets are
partners with leukocytes and other immunological effec-
tors (complement, TLR’s, PPAR’s, resolvins, PAF, CD40/
CD40L, etc.), amplifying or otherwise modulating those
effectors in ways distinctive for each condition, with
actions likely to be most prominent at the BBB.
A number of topics and many references were cut
from this review because of excessive length. They
include the role of platelets in several viral infections,
consideration of other possibly relevant receptors (e.g.,
vanilloids, vasopressin), new work dissecting prothrom-
botic from inflammatory pathways, and further details
on the topics covered. However, it is hoped that enough
has been said to inspire new respect for the humble lit-
tle platelet.
If this review succeeds in raising awareness of the
potential roles of platelets in neurodegenerative and
neuroinflammatory conditions, the labor of assembling
it will have been amply rewarded.
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